<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11517">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01789606</url>
  </required_header>
  <id_info>
    <org_study_id>B4371008</org_study_id>
    <secondary_id>AK-10-11</secondary_id>
    <nct_id>NCT01789606</nct_id>
  </id_info>
  <brief_title>Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet</brief_title>
  <official_title>Ibuprofen 600 mg Immediate Release/Extended Release (IR/ER) Caplet Self-Selection, Safety and Compliance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A self-selection and actual use trial to evaluate the extent to which consumers will
      appropriately select and use the 600 mg immediate release/extended release caplets and
      comply with dosing instructions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Self-Selection Arm: Percentage of participants who either correctly select to use or correctly de-select not to use the 600 mg IR/ER product, based on typical duration of pain.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Among those who select the 600 mg IR/ER product, the percentage of subjects who report their typical duration of pain, if left untreated, to be greater than or equal to 6 hours, will be considered to have corectly self-selected. Likewise, among those who do not select the 600 mg product who report their typical duration of pain, if left untreated, to be less than 6 hours will be considered to have correctly de-selected the IR/ER product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance Arm: Percentage of participants who use the product for more than 10 days (not necessarily consecutive) during the study and have an average daily dose of greater than 1600 mg.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Excessive use of the product is defined as:
(1) Using the product for more than 10 days (not necessarily consecutive) during the study and having an average daily dose greater than 1600 mg OR (2) Using the product for 10 days or less during the study, taking more than 20 caplets and having an average daily dose greater than 1600 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance Arm: Percentage of participants who use the product for 10 days or less during the study, take more than 20 caplets and have an average daily dose of greater than 1600 mg.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Excessive use of the product is defined as:
(1) Using the product for more than 10 days (not necessarily consecutive) during the study and having an average daily dose greater than 1600 mg OR (2) Using the product for 10 days or less during the study, taking more than 20 caplets and having an average daily dose greater than 1600 mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosing patterns among subjects who use the product excessively.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing patterns among subjects who are inappropriate self-selectors.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing patterns related to exceeding 1200 mg/day.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosing paterns related to exceeding 600 mg/dose.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily dose (within subject).</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum daily dose.</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">712</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Ibuprofen 600 mg Immediate Release/Extended Release Caplet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 mg Immediate Release/Extended Release Caplet</intervention_name>
    <description>Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.</description>
    <arm_group_label>Ibuprofen 600 mg Immediate Release/Extended Release Caplet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 12 years of age

          -  use of at least 5 doses per month of over-the-counter pain relievers over the past 3
             months

          -  provide written informed consent (subjects 12-&lt;18 years of age provide a written
             assent and parent/guardian will provide written informed consent)

          -  capable of and willing to swallow the study medication

        Exclusion Criteria:

          -  participated in other research studies in the last 6 months

          -  they or someone else in their household work for a pharmaceutical company, is a
             relative of study site personnel involved with the study, or an immediate family
             member is already enrolled in the study

          -  have a history of known allergies to ibuprofen, aspirin, or other NSAIDs

          -  have a history of heart surgery in the last 60 days or planned heart surgery in the
             next 60 days

          -  female subjects are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yorba Linda</city>
        <state>California</state>
        <zip>92886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Griffin</city>
        <state>Georgia</state>
        <zip>30224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Blaine</city>
        <state>Minnesota</state>
        <zip>55434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Elk River</city>
        <state>Minnesota</state>
        <zip>55330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Missouri</state>
        <zip>64485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taos</city>
        <state>New Mexico</state>
        <zip>87571</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montpelier</city>
        <state>Virginia</state>
        <zip>23192</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kenmore</city>
        <state>Washington</state>
        <zip>98028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Snohomish</city>
        <state>Washington</state>
        <zip>98290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4371008&amp;StudyName=Self-Selection%20and%20Actual%20Use%20Trial%20of%20Ibuprofen%20600%20mg%20Immediate%20Release/Extended%20Caplet</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 22, 2013</lastchanged_date>
  <firstreceived_date>September 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Self-selection and actual use/compliance trial.</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
